Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin effect on NETs in COPD
NCT03250689Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danirixin in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Nov 2017; status: terminated.
02
Drugs
danirixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03250689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250689.